🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Science has named the development of glucagon-like peptide-1 (#GLP1) agonists and this year's discovery that these drugs can blunt obesity-associated health problems as the 2023 #BreakthroughOfTheYear. Learn more: scim.ag/5c2 #BOTY

So excited to share CK Wong 's work with Daniel J Drucker showing that GLP-1RAs signal specific neural pathways in the CNS to elicit peripheral and systemic anti-inflammatory actions. The free full-text article is available here authors.elsevier.com/c/1iHB25WXUlSw…

Sinai Health's own Dr. Daniel J Drucker, whose foundational research underpins the year's top science breakthrough by Science Magazine, continues to unlock the mysteries of weight-loss drugs offering fresh insights into how they work in the body. 🧵 1/3 bit.ly/3Nx2GUw

Big congrats to Sinai Health’s Daniel J Drucker & co-laureates on winning VinFuture Prize for their work that led to popular diabetes & obesity drugs called GLP-1 agonists, which are helping millions of patients manage their disease 1/2

As #EidAlFitr begins, let us reflect on the values that we’ve nurtured throughout the holy month of Ramadan, and remind ourselves of our shared obligation to help the more vulnerable. This Eid, I renew my call for peace and dignity for all people regardless their background.

Thank you EASO for inviting me to present my research at the ECO 2024.

GLP-1RAs are neuroprotective in most preclinical studies. Here we detect robust glucose control & #weightloss yet no reduction in plaque, hippocampal IBA1 or GFAP + cells nor cytokine expression with semaglutide or tirzepatide in APP/S1 and 5XFAD mice sciencedirect.com/science/articl…

The AUB Neighborhood Initiative (AUBNI) has supported over 2,000 displaced people in Ras Beirut through training, health, and education. How to Help: Cash: Drop an envelope in the white box labeled Al Jar lil Jar near the Protection Office at AUB Main Gate. Transfers: Use the

Some new information about the anti-inflammatory actions of GIP from Rola Hammoud, PhD Gain and loss of GIPR signaling modifies gut inflammation in mice with 5FU-induced enteritis, with data on Tirzepatide & Semaglutide JCI insight Banting & Best Diabetes Centre Sinai Health CIHR

Two new studies zero in on the anti-inflammatory effects of the GLP-1 family of drugs, independent of weight loss, highlighting the gut-brain axis (modulating TLR response) and the gut GIP impact by Daniel J Drucker and colleagues cell.com/cell-metabolis… Cell Metabolism

Excited to share my work with Daniel J Drucker on the role for GIPR agonism alone and with GLP-1R agonism (Mounjaro/ Zepbound ) in the regulation of gut inflammation, and providing new insights on the localization of the GIP receptor in the gut. See paper here: insight.jci.org/articles/view/…

Patients with type 2 diabetes, obesity, and gut inflammation could clinically benefit from use of GIPR signaling agents. @danieljdrucker et al. demonstrate, for the first time, that activation vs. loss of GIP action impacts the extent of experimental gut inflammation in mice.

.Rola Hammoud, PhD explains their research in this video abstract: youtu.be/0KdTS04Y6hI

When asked to draw a scientist, school-age kids in the United States are increasingly sketching women, according to a study from 2018. Read more on #WomenInScienceDay: scim.ag/3WWWoSD

New insights into the actions of GIP agonism vs. antagonism on food intake and body weight in mice from Timo Muller and colleagues #weightloss #obesity Nature Metabolism Timo Müller Matthias Tschöp nature.com/articles/s4225…

Here Liu, Veniant & colleagues discover that a maritide like bispecific GIPR antagonist/GLP-1R agonist antibody requires both CNS GLP-1R/ GIPR for maximal #weightloss revealing loss of CNS GIPR augments the CNS actions of GLP-1 #obesity @naturemetabolism nature.com/articles/s4225…

Taking on the pseudoscience on aging and longevity companies/clinics with Dr. Mike Varshavski

Great new overview on the role Glp-1 medicines beyond weight and glucose management.